Dear Dr. Roach: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.
The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor–positive, HER2-negative stage II ...
However, long-term experience and specific clinical trials have revealed several limitations of tamoxifen in the adjuvant setting, including limited duration of effectiveness, continuing risk of ...
Purpose. The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed. Summary. AI therapy has become a standard of care for the treatment of most ...
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...
Kisqali combined with an aromatase inhibitor improved iDFS in hormone receptor-positive, HER2-negative early breast cancer, with a 30% risk reduction in DDFS and distant recurrence-free survival. The ...
DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...
A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast ...
Learn Look Locate and Walgreens Expand Breast Cancer Education with New Aromatase Inhibitor Resource
Learn Look Locate (LLL), a global leader in breast cancer education and patient support, is proud to announce the launch of a groundbreaking new educational webpage on aromatase inhibitors in ...
Innovent Biologics, Inc. and Eli Lilly and Co. LLY on Tuesday entered into a distribution and promotion agreement for Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results